Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis

  title={Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis},
  author={Md. Asiful Islam and Fahmida Alam and Mohammad Amjad Kamal and Siew Hua Gan and Teguh Haryo Sasongko and Kah Keng Wong},
  journal={Frontiers in Aging Neuroscience},
Growing evidences are supporting towards the involvement of antiphospholipid antibodies [aPLs e.g., lupus anticoagulant (LA), anticardiolipin (aCL) and anti-β2-glycoprotein I (anti-β2-GPI) antibodies] in various neurological manifestations including migraine, epilepsy and dementia in the presence or absence of autoimmune diseases such as antiphospholipid syndrome or systemic lupus erythematosus. The aim of this systematic review and meta-analysis was to assess the presence of aPLs in dementia… Expand
Prevalence of antiphospholipid antibodies in Behçet's disease: A systematic review and meta-analysis
It is established that there is a significantly high prevalence of aPLs in patients with BD when compared to controls, and no significant publication bias was detected from contour-enhanced and trim and fill funnel plots or Begg's and Egger’s tests. Expand
Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review.
A systematic review searching MEDLINE via PubMed and Cochrane databases for observational studies reporting on the association between aPL and dementia in the general population, in subjects carrying aPL, in patients with cognitive disorder/dementia, and in primary and secondary APS found little evidence on anti β2-Glycoprotein I exists. Expand
Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis.
Since none of the epilepsy subjects exhibited any comorbid autoimmune disorders, significant presence of aCL and anti-β2-GPI antibodies indicate towards their contribution in immune-mediated general pathogenesis of epilepsy. Expand
Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy
Known neurological manifestations of APS are summarized, revisiting pathogenesis and current treatment options are revisited, and the reason why only a subgroup of patients develop non-criteria nervous system disorders is explained. Expand
Antiphospholipid antibodies and antiphospholipid syndrome in cancer: Uninvited guests in troubled times.
More researches should be conducted on the association between the aPLs and malignancies towards the potential impact on understanding the pathogenicity and treatment when cancer and APS coexists. Expand
Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers
An accurate risk stratification is recommended for aPL-positive subjects in order to prevent both venous and arterial thrombotic complications, and an overview of the main antithrombosis and risk assessment strategies in aPL carriers is provided. Expand
Genetic risk factors in thrombotic primary antiphospholipid syndrome: A systematic review with bioinformatic analyses.
According to a systematic review, 16 genes contribute significantly in patients with thrombotic primary APS when compared with controls, and these genes are expressed in 32 different organs and may pose higher risk of developingThrombosis anywhere in the body ofPrimary APS patients. Expand
16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome
The task force concluded that APS does not have a uniform definition given the heterogeneity of the clinical presentations and different aPL profiles, and risk stratification strategies in aPL-positive patients can be useful in clinical practice. Expand
Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin
A combined brain/heart MRI may be considered in APS patients at high risk for CVD/stroke, such as systemic lupus erythematosus with high-risk aPL profile or high scores in CVD risk prediction models. Expand
Changes in Cerebrospinal Fluid Tau and β-Amyloid Levels in Diabetic and Prediabetic Patients: A Meta-Analysis
A systematical analysis of published studies that evaluated the AD-type biomarkers in the CSF of subjects with diabetes, IR, or hyperinsulinemia revealed that the relationship between (pre)diabetic conditions and AD- type biomarker status in theCSF was subjective to clinical characteristics. Expand


Comorbid association of antiphospholipid antibodies and migraine: A systematic review and meta-analysis.
The presence of aCL or anti-β2GPI antibodies was significant in migraine patients compared to healthy controls, suggesting an involvement of these autoantibodies in migraine attack. Expand
Coexistence of antiphospholipid antibodies and cephalalgia
Higher frequency of comorbidity between antiphospholipid antibodies and headache was observed in healthy individuals and patient cases, and experimental studies are warranted to evaluate the aPLs-induced pathogenic mechanism of headache. Expand
Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants
CAC-positive APS patients seem to be at risk for developing dementia with age, suggesting a pathogenic role for prolonged exposure to elevated aPL, and aPTT due to circulating anticoagulants (CAC) may serve as a more specific laboratory marker of APS. Expand
Vascular dementia and anticardiolipin antibodies.
There was a significant difference in the prevalence of high levels of anticardiolipin antibodies between the group of patients with vascular dementia and the control group, which proves that anticARDiolipIn antibodies present a risk factor for vascular dementia. Expand
Dementia and Antiphospholipid Antibodies
All the patients with high aPLAb levels were diagnosed clinically as having dementia of the Alzheimer type, except for 1 who had mixed dementia, and none had features of an immune-mediated disease. Expand
The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus.
LA positivity is associated with subclinical nervous system compromise, and a pattern of deficits compatible with subcortical involvement, possibly on the basis of ongoing LA-related microthrombotic events or vasculopathy. Expand
Prospective study of anticardiolipin antibodies in stroke.
Over 2 years, 104 patients underwent clinical evaluation and laboratory screening for the presence of abnormal anticardiolipin antibodies to determine the profile of laboratory and clinical findingsExpand
Antiphospholipid Antibodies and Stroke in Young Women
The results from this study support the importance of antiphospholipid antibodies as an independent risk factor for stroke in young women. Expand
Studies on correlation of anticardiolipin antibodies and multi-infarct dementia
Serum levels of IgG-ACLA may be related with the development of MID and the changes of anticardiolipin antibodies in patients with multi-infarct dementia and its clinical significance are studied. Expand
Neurological presentations of the antiphospholipid syndrome: three illustrative cases
This work proposes to search the presence of aPLs in any case of young adults’ stroke, unexplained dementia, and acquired chorea, and presents three cases of antiphospholipid syndrome revealed by CNS manifestations. Expand